CEA is not associated with survival outcomes in SCCA and is not a clinically relevant biomarker in this disease

Oncotarget released “CEA as a blood-based biomarker in anal cancer“, Which reported that mean carcinoembryonic antigen (CEA) among clinical subgroups at the time of presentation at our facility was highest in patients with anal metastatic squamous cell carcinoma (SCCA) to visceral organs, but this finding was not statistical significant by ANOVA.

By clinical subgroup, the percentage of patients with abnormally elevated CEA was highest in patients with metastatic lymph node disease, followed by recurrent / unresectable SCCA and metastatic SCCA in visceral organs and statistically significant between groups.

Using RECIST criteria for tumor progression and disease response, the mean change in CEA in patients with progression was an increase of 19 ng / ml compared to a change of -7.3 ng / ml in patients with disease response.

The authors also assessed whether CEA levels were associated with survival outcomes in all patients with metastatic SCCA, and found no correlation between CEA and probability of survival in a ROC analysis.

Despite interesting patterns of abnormally high CEA in SCCA patients with advanced disease and the correlation of increased CEA with disease progression, CEA is not associated with survival outcomes in SCCA and is not a clinically relevant biomarker in this disease.

CEA is not associated with survival outcomes in SCCA and is not a clinically relevant biomarker in this disease

Dr. Van K. Morris of the University of Texas – MD Anderson Cancer Center said: “Squamous cell carcinoma of the anal canal (SCCA) is a rare cancer of the anogenital tract with an estimated incidence of approximately 8,500 new cases and 1,350 deaths in 2020 in the US in 2020, accounting for 2-3% of all gastrointestinal cancers.

Routine, readily available blood-based markers are widely used in the clinical treatment of patients with solid tumors in a variety of clinical settings.

For example, trends in biomarkers such as carcinoembryonic antigen, carbohydrate antigen 19-9, prostate-specific antigen and carbohydrate antigen 125 over time can serially refer to patients with colon cancer, pancreatic cancer, prostate cancer or a surrogate for changes in the amount of the tumor present.

To date, a blood-based biomarker for tracking responses to HPV-associated cancers has not been available to clinical oncologists for routine use.

Among anal cancer patients, a series studied 106 patients with early-stage SCCA who were definitely treated with chemoradiotherapy and found no clinical benefit in measuring CEA in this subset of anal cancer patients.

Since no blood-based biomarkers are currently available in a CLIA-certified laboratory for the routine management of SCCA, we conducted a retrospective study at a single institution to match the serum CEA levels with the clinical and pathological outcomes in patients at all stages and Correlate presentations from SCCA.

The Morris Research Team concluded in his Oncotarget Research results,”We report on the largest series describing CEA as a serum biomarker for patients with metastatic SCCA. Our results may not provide definitive support for the use of a routinely used blood-based assay to treat patients with SCCA and should guide clinicians in finding alternative approaches to tracking response to treatment for this disease. Nevertheless, new approaches with serum biomarkers are needed for patients with this rare but increasingly diagnosed malignancy.


DOI – https: //doi.Organization/10.18632 /onkoziel.27959

Full text – https: //www.onkoziel.com /Items/27959 /Text/

Correspondence – Van K. Morris – [email protected]

carcinoembryonic antigen,
Squamous cell carcinoma of the anal canal,
Anal cancer,

over Oncotarget

Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal that covers research on all aspects of oncology.

Learn more about it Oncotarget, please visit https: //www.onkoziel.com or connect with:

SoundCloud – https: //Cloud of sound.com /oncotarget
Facebook – Oncotarget / ”> https: //www.Facebook.com /Oncotarget/
Twitter –https: //tweet.com /oncotarget
LinkedIn – https: //www.linked.com /Companies/oncotarget
Pinterest – https: //www.pinterest.com /Onkoziel /
Reddit – Oncotarget / ”> https: //www.reddit.com /User/Oncotarget/

Oncotarget is published by Impact Journals, LLC, please visit https: //www.ImpactJournals.com or connect with @ImpactJrnls

Media contact

[email protected]
18009220957 × 105

Copyright © 2021 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC

https: //www.onkoziel.com /News/pr /cea-as-a-blood-based-biomarker-in-anal-cancer /


Please enter your comment!
Please enter your name here